Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia

International Journal of Neuropsychopharmacology

Volumn 7, Issue 4, 2004, Pages 495-500

  Pae, Chi Un ^a   Yu, Hye Sook ^a   Kim, Jung Jin ^a   Lee, Chang Uk ^a   Lee, Soo Jung ^a   Jun, Tae Youn ^a   Lee, Chul ^a   Paik, In Ho ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Korean; Quinone oxidoreductase (NQO1) gene polymorphism (609C T); Schizophrenia

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; QUINONE OXIDOREDUCTASE GENE; RATING SCALE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KOREA; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

EID: 10644226033     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004419     Document Type: Article

References (21)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington DC: American Psychiatric Association.
2. Benkmann HG, Cho YH, Singh S, Wimmer U, Lee CC, Kim IK, Paik YK, Goedde HW (1989). Red cell enzyme and serum protein polymorphisms in South Korea. Human Heredity 39, 263-270.
3. Cadenas E (1995). Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochemistry and Pharmacology 49, 127-140.
4. Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L (1999). Association of the NAD(P)H:quinone oxidoreductase 609C-> T polymorphism with a decreased lung cancer risk. Cancer Research 59, 3045-3048.
5. Drukarch B, van Muiswinkel FL (2000). Drug treatment of Parkinson's disease. Time for phase II. Biochemistry and Pharmacology 59, 1023-1031.
6. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM-IV - Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press.
7. Guy W (1976). Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology (revised). US DHEW publication (pp. 534-537). Department of Health, Education and Welfare, Washington, DC.
8. Harada S, Tachikawa H, Kawanishi Y (2001). Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. Biochemical and Biophysical Research Communications 281, 267-271.
9. Hori H, Ohmori O, Matsumoto C, Shinkai T, Nakamura J (2003). NAD(P)H:quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia. Psychiatry Research 118, 235-239.
10. Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T, Nakamura J (2000). Manganese Superoxide dismutase gene polymorphism and schizophrenia : relation to tardive dyskinesia. Neuropsychopharmacology 23, 170-177.
11. Kay SR, Opler LA, Lindenmayer JP (1988). Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Research 23, 99-110.
12. Lohr JB, Kuczenski R, Niculescu AB (2003). Oxidative mechanisms and tardive dyskinesia. CNS Drugs 27, 47-62.
13. Pae CU, Kirn JJ, Lee SJ, Lee CU, Lee C, Paik IH, Park HR, Yang S, Serretti A (2003). Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population. Progress in Neuropsychopharmacology and Biological Psychiatry 27, 519-523.
14. Pae CU, Yu HS, Kim JJ, Kim W, Lee KU, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Serretti A (In Press). Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatric Genetics.
15. Pritchard JK, Rosenberg NA (1999). Use of unlinked genetic markers to detect population stratification in association studies. American Journal of Human Genetics 65, 220-228.
16. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 39, 486-487.
17. Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9, 113-121.
18. Smythies J (2002). The adrenochrome hypothesis of schizophrenia revisited. Neurotoxicity Research 4, 147-150.
19. Smythies JR (1997). Oxidative reactions and schizophrenia: a review-discussion. Schizophrenia Research 24, 357-364.
20. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, Gibson NW (1992). NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Research 52, 797-802.
21. Zhang Z, Zhang X, Hou G, Sha W, Reynolds GP (2002). The increased activity of plasma manganese Superoxide dismutase in tardive dyskinesia is unrelated to the A1a-9Va1 polymorphism. Journal of Psychiatry Research 36, 317-324.